How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,151 results for

Peripheral Neuropathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

17141. Neurogenic bladder due to peripheral neuropathy and a visual disturbance in an elderly man with systemic lupus erythematosus. (PubMed)

Neurogenic bladder due to peripheral neuropathy and a visual disturbance in an elderly man with systemic lupus erythematosus. A 63 year old man with central nervous system lupus with a neurogenic bladder and visual disturbance is described. The diagnosis of neurogenic bladder, attributed to peripheral neuropathy, was made on the basis of cystometrography and clinical symptoms. A brain magnetic resonance imaging scan showed gliosis along the cerebral vessels and the optic nerve. This case shows (...) that systemic lupus erythematosus can be accompanied by a peripheral neurogenic bladder and visual disturbance, and that these symptoms may not improve despite the amelioration of other lupus symptoms on treatment with steroids.

Full Text available with Trip Pro

1992 Annals of the Rheumatic Diseases

17142. Flecainide induced peripheral neuropathy. (PubMed)

Flecainide induced peripheral neuropathy. 1330141 1992 12 17 2018 11 13 0959-8138 305 6857 1992 Oct 03 BMJ (Clinical research ed.) BMJ Flecainide induced peripheral neuropathy. 810 Palace J J Department of Neurology Guy's Hospital, London. Shah R R Clough C C eng Case Reports Journal Article England BMJ 8900488 0959-8138 K94FTS1806 Flecainide AIM IM Flecainide adverse effects Humans Male Middle Aged Peripheral Nervous System Diseases chemically induced 1992 10 3 1992 10 3 0 1 1992 10 3 0 0

Full Text available with Trip Pro

1992 BMJ : British Medical Journal

17143. Peripheral neuropathy in a patient receiving enalapril. (PubMed)

Peripheral neuropathy in a patient receiving enalapril. 1336423 1993 02 18 2018 11 13 0959-8138 305 6865 1992 Nov 28 BMJ (Clinical research ed.) BMJ Peripheral neuropathy in a patient receiving enalapril. 1332 Hormigo A A Instituto Português de Oncologia, Lisbon. Alves M M eng Case Reports Journal Article England BMJ 8900488 0959-8138 69PN84IO1A Enalapril AIM IM Enalapril adverse effects Female Humans Middle Aged Peripheral Nervous System Diseases chemically induced 1992 11 28 1992 11 28 0 1

Full Text available with Trip Pro

1992 BMJ : British Medical Journal

17144. Hypoxia, almitrine, and peripheral neuropathy. (PubMed)

Hypoxia, almitrine, and peripheral neuropathy. 2548298 1989 09 08 2018 11 13 0040-6376 44 4 1989 Apr Thorax Thorax Hypoxia, almitrine, and peripheral neuropathy. 247-50 Howard P P Department of Medicine, University of Sheffield. eng Journal Article Review England Thorax 0417353 0040-6376 0 Piperazines 9A1222NBG4 Almitrine IM Almitrine Humans Hypoxia drug therapy etiology Lung Diseases, Obstructive complications drug therapy Peripheral Nervous System Diseases chemically induced Piperazines

Full Text available with Trip Pro

1989 Thorax

17145. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. (PubMed)

Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. The potential of the aldose reductase inhibitor ponalrestat (600 mg daily) to ameliorate diabetic neuropathy was evaluated in 259 diabetes mellitus patients with peripheral neuropathy (defined by abnormal vibration perception threshold and abnormal peroneal motor conduction (...) with an increased duration of diabetes was not tested. Patients with an abnormal heart rate reaction to standing (abnormal 30:15 ratio; n = 84) on ponalrestat did not deteriorate in this autonomic nerve function test as shown in those on placebo. In conclusion, ponalrestat did not improve peripheral nerve function in diabetes mellitus patients with signs of peripheral neuropathy, although it did ameliorate a deterioration in autonomic nerve function in diabetic patients with signs of autonomic neuropathy.

1992 Journal of diabetes and its complications

17146. A study of the effects of isaxonine on vincristine-induced peripheral neuropathy in man and regeneration following peripheral nerve crush in the rat. (PubMed)

A study of the effects of isaxonine on vincristine-induced peripheral neuropathy in man and regeneration following peripheral nerve crush in the rat. Administration of isaxonine (6 mg/kg powdered diet) had no effect on regeneration following sciatic nerve crush in the rat. In 10 patients undergoing treatment with vincristine (1.4 mg/m2 twice monthly) development of peripheral neuropathy was quantitated by neurological symptoms, signs and electrophysiological tests. Five also received isaxonine (...) (1.5 g daily). All patients developed evidence of neuropathy, but in none was it severe. The three lowest disability scores were obtained in isaxonine treated patients, but the highest score was also in an isaxonine treated patient. The equivocal findings in this small study could not be amplified because the drug was withdrawn from clinical use on account of its hepatotoxicity.

Full Text available with Trip Pro

1985 Journal of neurology, neurosurgery, and psychiatry

17147. Clinical observation on treatment of diabetic peripheral neuropathy with reinforced tianma duzhong capsule. (PubMed)

Clinical observation on treatment of diabetic peripheral neuropathy with reinforced tianma duzhong capsule. 10921146 2000 08 09 2016 10 20 0255-2922 19 3 1999 Sep Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan J Tradit Chin Med Clinical observation on treatment of diabetic peripheral neuropathy with reinforced tianma duzhong capsule. 182-4 Li M M Beijing Hospital. Wang X X eng Clinical Trial Journal Article Randomized Controlled Trial China J Tradit Chin Med 8211546 (...) 0255-2922 0 Capsules 0 Drugs, Chinese Herbal IM Adult Aged Capsules Diabetes Mellitus, Type 2 drug therapy Diabetic Neuropathies drug therapy Drugs, Chinese Herbal therapeutic use Female Humans Male Middle Aged 2000 8 2 11 0 2000 8 12 11 0 2000 8 2 11 0 ppublish 10921146

2000 Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

17148. A clinical study on treatment of diabetic peripheral neuropathy with tang zhi min capsules. (PubMed)

A clinical study on treatment of diabetic peripheral neuropathy with tang zhi min capsules. 11263276 2001 05 03 2016 10 20 0255-2922 20 4 2000 Dec Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan J Tradit Chin Med A clinical study on treatment of diabetic peripheral neuropathy with tang zhi min capsules. 258-61 Ren H H Baoding Municipal Hospital of Traditional Chinese Medicine, Baoding 071000, Hebei Province. eng Clinical Trial Journal Article Randomized Controlled Trial (...) China J Tradit Chin Med 8211546 0255-2922 0 Capsules 0 Drugs, Chinese Herbal IM Adult Aged Blood Viscosity Capsules Diabetic Neuropathies blood drug therapy Drugs, Chinese Herbal therapeutic use Female Humans Male Middle Aged 2001 3 27 10 0 2001 5 5 10 1 2001 3 27 10 0 ppublish 11263276

2001 Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan

17149. Motor neuropathy in porphobilinogen deaminase–deficient mice imitates the peripheral neuropathy of human acute porphyria (PubMed)

Motor neuropathy in porphobilinogen deaminase–deficient mice imitates the peripheral neuropathy of human acute porphyria Acute porphyrias are inherited disorders caused by partial deficiency of specific heme biosynthesis enzymes. Clinically, porphyrias are manifested by a neuropsychiatric syndrome that includes peripheral neuropathy. Although much is known about the porphyrias' enzyme defects and their biochemical consequences, the cause of the neurological manifestations remains unresolved (...) . We have studied porphyric neuropathy in mice with a partial deficiency of porphobilinogen deaminase (PBGD). PBGD-deficient mice (PBGD-/-) imitate acute porphyria through massive induction of hepatic delta-aminolevulinic acid synthase by drugs such as phenobarbital. Here we show that PBGD-/- mice develop impairment of motor coordination and muscle weakness. Histologically femoral nerves of PBGD-/- mice exhibit a marked decrease in large-caliber (>8 microm) axons and ultrastructural changes

Full Text available with Trip Pro

1999 Journal of Clinical Investigation

17150. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). (PubMed)

Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Identification of risk factors for development of diabetic sensorimotor peripheral neuropathy (DSPN) and diabetic autonomic neuropathy (DNA) may help to prevent or modify these complications. The ABCD Trial, a prospective study of diabetic complications, has identified risk factors of the presence and staging of peripheral neuropathy based on neurological symptom scores

1998 Muscle & nerve

17151. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. (PubMed)

Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. Clinical investigations with the aldose reductase inhibitor sorbinil in patients with peripheral neuropathy due to diabetes are described. After an improvement in motor and sensory nerve conduction velocities was demonstrated in asymptomatic diabetic patients taking sorbinil (compared with velocities during a placebo period), 11 patients with painful diabetic neuropathy were treated (...) conduction velocity and cardiac autonomic function were also documented. Cardiac autonomic neuropathy was studied in 36 patients in a double-blind, placebo-controlled, randomized, noncrossover trial. Patients received one 250-mg sorbinil tablet or one placebo tablet daily for six weeks, after a one-week baseline period. Glycemic control did not change during the study period, as indicated by unaltered glycohemoglobin levels. Response was assessed by expiration-inspiration ratios, obtained

1985 The American journal of medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>